Avantect Ovarian Cancer Test
Use
The Avantect Ovarian Cancer Test is a novel cell-free DNA-based blood test aimed at aiding in the earlier diagnosis of ovarian cancer in women at high risk. The test offers the potential for improved survival by detecting abnormal signals associated with ovarian cancer. It provides a qualitative result indicating the presence or absence of an abnormal signal, which, if present, suggests further oncological evaluation and imaging studies, such as TVUS or MRI, may be warranted.
Special Instructions
Not provided.
Limitations
The Avantect Ovarian Cancer Test, like all screening tests, has limitations. Not all ovarian cancers will be detected, and there is a chance for false-positive or false-negative results. It is possible that patients with ovarian cancer may receive a 'Signal not detected' result, and vice versa. The test was developed in a CLIA-certified and CAP-accredited laboratory but is not FDA cleared or approved, underscoring the importance of considering other diagnostic procedures like imaging and biopsy for comprehensive assessment.
Methodology
Other
Biomarkers
Abnormal signal associated with ovarian cancer
Analyte
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
A routine blood draw is required for the test.